{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-086244","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-08-06T21:25:33+00:00","discovered_at":"2026-08-06T21:26:00.386386+00:00","generated_at":"2026-08-06T21:26:05.907346+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Apimeds appoints Dr. Christopher Kim as Chief Scientific Officer","bullets":["Dr. Christopher Kim appointed Chief Scientific Officer effective August 5, 2026.","He will lead scientific, clinical, and regulatory development of the APITOX program.","Dr. Kim has extensive expertise in APITOX research, development, and clinical advancement.","Appointment provides continuity and strengthens long-term development strategy toward commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-086244","json":"https://secwatch.observer/filing/0001213900-26-086244.json","markdown":"https://secwatch.observer/filing/0001213900-26-086244.md","text":"https://secwatch.observer/filing/0001213900-26-086244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026086244/0001213900-26-086244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026086244/ea0301025-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T21:26:05.907346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}